30 results on '"Pater, Joseph L."'
Search Results
2. Application of Value Frameworks to the Design of Clinical Trials: The Canadian Cancer Trials Group Experience
3. A Canadian Prospective Study of Linkage of Randomized Clinical Trial to Cancer and Mortality Registry Data
4. Re: Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17
5. Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17
6. Treatment of locally advanced breast cancer
7. Application of Value Frameworks to the Design of Clinical Trials: The Canadian Cancer Trials Group Experience.
8. Ovarian Ablation as Adjuvant Therapy for Premenopausal Women With Breast Cancer—Another Step Forward
9. Ethics and industry-sponsored research
10. Enrollment of elderly patients in cancer treatment trials in Canada: Why is age a barrier?
11. # 1635/Maintaining Compliance in Quality of Life Data Completion in Clinical Trials: The National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) Experience
12. The Timing of Baseline Quality of Life in Clinical Trials
13. Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17
14. Abstract P3-09-02: Association between definitive surgery and times to administration of adjuvant chemotherapy and outcomes in early breast cancer: Analysis of adjuvant studies conducted by NCIC Clinical Trials Group (NCIC CTG)
15. Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17.
16. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen.
17. Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17.
18. Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17.
19. Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial.
20. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.
21. Cardiovascular Risk of Celecoxib in 6 Randomized Placebo-Controlled Trials
22. A Phase III Randomized, Double-Blind, Placebo-Controlled Study Evaluating Dextromethorphan Plus Slow-Release Morphine for Chronic Cancer Pain Relief in Terminally Ill Patients
23. RESPONSE
24. Reduction in Clinical Response to Empiric Antimicrobial Therapy of Febrile Granulocytopenic Patients Receiving TMP/SMX Infection Prophylaxis
25. Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17
26. Carryover and the Two-Period Crossover Clinical Trial
27. Comparison of Outcomes By Age of Patients with Limited Stage Hodgkin Lymphoma Treated with ABVD Alone; A Secondary Analysis of the Canadian Cancer Trial Group HD.6 Trial
28. RESPONSE.
29. Application of Value Frameworks to the Design of Clinical Trials: The Canadian Cancer Trials Group Experience.
30. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.